SUBSCRIBE
SUBSCRIBE

Nick Paul Taylor

Nick is a freelance writer who has been reporting on the global life sciences industry since 2008. With a BSc in biology, Nick writes about the science and business of biopharma and medtech for numerous healthcare publications. He can be reached at nick.paul.taylor@gmail.com or on LinkedIn.

Corporate headquarters of Novo Nordisk in Denmark
Business
JPM26: Novo Refocuses on Diabetes and Obesity Amid Push To Expand GLP-1 Market
After a period of diversification, Novo Nordisk is returning to its roots by focusing on the 2 billion people with diabetes, obesity or overweight.
January 14, 2026
 · 
3 min read
 · 
Nick Paul Taylor
Pictured: Eli Lilly's headquarters in Indianapolis
Business
JPM26: Lilly Plots Path to Dominance as Obesity Market Enters a New Era
BMO analysts say Eli Lilly is well-positioned to maintain its lead in the ballooning weight loss space, predicting “strengthening leadership in obesity and beyond” as portfolios expand and patient access improves.
January 14, 2026
 · 
2 min read
 · 
Nick Paul Taylor
Johnson & Johnson's business center in Switzerland
Manufacturing
J&J To Add 500 Jobs at New Plant, Doubling Down on North Carolina
Johnson & Johnson’s second facility in Wilson, North Carolina, is part of a $55 billion push to make all advanced medicines used in the U.S. domestically.
January 13, 2026
 · 
2 min read
 · 
Nick Paul Taylor
Manhattan, New York USA - July 9, 2011: Pfizer letter sign on the building's Headquarters. Pfizer's is the largest pharmaceutical company in the world.
Business
JPM26: Pfizer Fast-Tracks Obesity Programs in Race Against Patent Cliff
Facing the loss of exclusivity on key products, Pfizer has pulled forward its lead obesity asset into Phase III and targeted a 2028 launch. CEO Albert Bourla explained the pharma’s strategy at J.P. Morgan on Monday.
January 13, 2026
 · 
3 min read
 · 
Nick Paul Taylor
FDA signage at its headquarters in Maryland
Manufacturing
AbbVie, Amgen, Lilly Lead Calls for FDA To Update Post-Approval Change Rules
Drugmakers told the FDA that inflexible post-approval change requirements are among the top regulatory barriers to the reshoring of pharmaceutical manufacturing.
January 13, 2026
 · 
5 min read
 · 
Nick Paul Taylor
AbbVie's office in South San Francisco, California
Cancer
AbbVie Bets Nearly $5B on RemeGen To Vie for Position in Hot Bispecific Market
The deal, which sees AbbVie paying RemeGen $650 million upfront, gives the pharma ex-China rights to the biotech’s PD-1/VEGF bispecific antibody—a modality being targeted by companies including BMS, Merck and Pfizer.
January 12, 2026
 · 
2 min read
 · 
Nick Paul Taylor
Cambridge, USA - 16 August 2024. View of Moderna office entrance with logo sign, Biotechnology industry
Business
Moderna Hits 2025 Revenue Goal as Operating Costs Fall Faster than Forecast
While Moderna’s full-year sales landed in the upper end of its target range, Jefferies analysts said further reductions are needed if the biotech hopes to hit its 2028 break-even target.
January 12, 2026
 · 
2 min read
 · 
Nick Paul Taylor
Distorted pink piggy bank squeezed in vise , symbolizing financial stress and debt. with plain blue background
Venture capital
Early-Stage Biotechs Feel the Squeeze as Funding Favors Derisked Assets: JPM
Heightened diligence standards and longer decision timelines for early-stage startups slowed venture activity last year, J.P. Morgan found in a report published ahead of the bank’s annual healthcare conference in San Francisco.
January 12, 2026
 · 
2 min read
 · 
Nick Paul Taylor
A look into the future. Concept. stock photo
Manufacturing
2026: Putting the Reindustrialization Mandate Into Practice
Industry leaders are focused on the resilience of key starting material supply and the knock-on effects of automation in the new year.
January 6, 2026
 · 
4 min read
 · 
Nick Paul Taylor
Oct 9, 2019 Milpitas / CA / USA - Johnson & Johnson Vision offices in Silicon Valley; Johnson & Johnson Vision Care, Inc. is part of the American multinational corporation Johnson&Johnson
Immunology and inflammation
J&J Stops Mid-stage Eczema Trial as $1.25B Asset Misses Efficacy Mark
J&J paid Numab Therapeutics $1.25 billion upfront for the asset in 2024 based on the belief that its dual mechanism of action could improve on existing therapies.
January 5, 2026
 · 
2 min read
 · 
Nick Paul Taylor
AbbVie's office in South San Francisco, California
Lung cancer
AbbVie Challenges Amgen With $100M Upfront for Trispecific Lung Cancer Drug
The Illinois-based pharma has committed more than $1 billion in milestones to secure rights to ZG006 and join a who’s who of drugmakers targeting the DLL3 protein.
January 5, 2026
 · 
2 min read
 · 
Nick Paul Taylor
Business growth or increase in professional income, business operations, investment profits or interest on savings, increase in interest rates, businessman holding gold coins forming a growing arrow symbol.
Drug pricing
Pfizer Leads Industry-Wide Surge in Drug Prices for 2026 Despite Political Pressure
More than a dozen pharmas have recently struck deals with the White House to lower drug prices. Nevertheless, drugmakers reportedly plan to raise the U.S. prices of at least 350 branded medications.
January 2, 2026
 · 
2 min read
 · 
Nick Paul Taylor
whale watching boat in Iceland, group of people look at whale
Approvals
Vanda Ends 40-Year Motion Sickness Drug Drought With FDA Approval for Nereus
Jefferies analysts envision a steady launch curve that could ultimately drive meaningful sales from people who are dissatisfied with existing treatments.
January 2, 2026
 · 
3 min read
 · 
Nick Paul Taylor
Recession arrow, Graph showing business decline on led screen
Complete response letters
FDA Rejects Corcept and Outlook Filings, Crushing Stock Prices
Both companies received agency requests for more evidence of the effectiveness of their therapies.
January 2, 2026
 · 
2 min read
 · 
Nick Paul Taylor
Diet pills and bottle of diet supplements with measuring tape
GLP-1
Novo’s Wegovy Pill Wins Obesity Approval, Securing Lead in Oral GLP-1 Race
Analysts called the approval a much-needed win for Novo Nordisk, but warned that the company could struggle to grow sales once rival drugs come to market.
December 23, 2025
 · 
2 min read
 · 
Nick Paul Taylor
Load More